Taysha Gene Therapies heads into the final weeks before its August earnings date with short sellers trimming exposure and the lending pool remaining comfortably loose — a setup that contrasts with the stock's still-elevated headline short interest figure.
The short interest story is one of steady retreat. At 13.1% of the free float, the short position remains meaningfully large. But it has fallen roughly 10% over the past month, stepping down from around 40 million shares in mid-May to 36 million today. That direction matters. The pace of short covering has been deliberate rather than panicked, with no sharp single-session moves. More telling is the state of the lending market: availability is running at 742%, meaning there are more than seven shares available to borrow for every one already shorted. That is well above the tightest level seen in the past year, when availability compressed to around 64%. Cost to borrow is minimal at 0.51%, and has actually drifted lower over the past month. The lending market, in short, offers no squeeze pressure whatsoever. Options tell a similar story — the put/call ratio of 0.04 is fractionally below its 20-day average and near the lowest level of the past year, pointing to call-side dominance and no meaningful demand for downside protection. The ORTEX short score of 67.5 has also softened from 69 at the start of the month, consistent with the easing short pressure.
The Street is firmly bullish on the thesis, even if the consensus is a little dated. Ten analysts carry Buy-equivalent ratings, with a mean price target around $12.20 — roughly double the current price of $5.85. The most recent target lift of note came from Canaccord Genuity in early April, raising to $17. Needham moved its target up to $12 in March. Both are more than six weeks old, but no analyst has walked away from the name. The bull case centres on Taysha's FDA-aligned manufacturing programme for TSHA-102, its Rett syndrome gene therapy, and the BLA-enabling batch run now underway. The bear case is familiar for any pre-revenue gene therapy: execution risk on the regulatory path, competition from other AAV platforms, and the near-certainty of additional capital raises. The price-to-book multiple of 25.6x reflects the market assigning substantial option value to a programme that has yet to generate revenue.
Institutional ownership is worth noting here. The register is dense with specialist healthcare funds. RA Capital and Avoro together hold about 15% of shares. Vestal Point Capital added 4.25 million shares in Q1 — a meaningful new position. Goldman Sachs Asset Management added nearly 8.9 million shares in April. FMR added roughly 940,000 shares. On the other side, RTW Investments trimmed by 2.7 million shares in Q1. The insider picture is less constructive: President Sukumar Nagendran sold 200,000 shares in April at $4.46, and there were cluster sells in January from the CEO, CFO, and President. The net insider figure over 90 days shows shares sold rather than bought — though the trade values are modest relative to the institutional flows moving in the opposite direction.
The stock gained 9% on the week to $5.85, roughly in line with peers. NGNE added 1.9% and ABEO gained 3.7% on the week. ARTV was the standout in the peer group, up 22.6%. CADL was the exception, falling 8%. TSHA's 1-month performance remains slightly negative at -1.8%, even as the week's bounce helped the broader group. Earnings history offers a clear caution: the last two prints each produced a negative one-day reaction of around 3-4%, with five-day moves also firmly lower. The next report lands August 12.
The key variable between now and that date is whether a clinical data update on TSHA-102 arrives in time to reset the debate — the bull case explicitly flags this as the next potential catalyst, and the shape of short covering and institutional building suggests some investors are already positioned for it.
See the live data behind this article on ORTEX.
Open TSHA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
